Clinical Trial Update: An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS [Phase 2]

View source ↗

Summary

Open-label extension update for a Phase 2 study evaluating CNM-Au8 in early symptomatic ALS patients on stable background therapy to slow disease progression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• CNM-Au8 (CNM-Au8)

Snippet

Sponsor: Clene Nanomedicine | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING